Menu
Search
|

Menu

Close
X

Eli Lilly and Co LLY.N (New York Stock Exchange)

113.31 USD
-0.28 (-0.25%)
As of 4:00 PM EDT
chart
Previous Close 113.59
Open 114.00
Volume 1,158,439
3m Avg Volume 964,010
Today’s High 114.19
Today’s Low 112.42
52 Week High 116.61
52 Week Low 73.70
Shares Outstanding (mil) 1,073.99
Market Capitalization (mil) 124,002.60
Forward P/E 68.72
Dividend (Yield %) 0.56 ( 1.95 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.43 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY18
12,055
FY17
22,871
FY16
21,222
FY15
19,959
EPS (USD)
FY18
0.908
FY17
1.621
FY16
2.578
FY15
2.261
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
68.72
32.14
Price to Sales (TTM)
vs sector
5.19
6.55
Price to Book (MRQ)
vs sector
10.85
4.00
Price to Cash Flow (TTM)
vs sector
36.46
21.51
Total Debt to Equity (MRQ)
vs sector
105.75
14.15
LT Debt to Equity (MRQ)
vs sector
79.36
11.31
Return on Investment (TTM)
vs sector
6.02
12.83
Return on Equity (TTM)
vs sector
13.80
14.95

EXECUTIVE LEADERSHIP

David Ricks
Chairman of the Board, President, Chief Executive Officer, Since 2017
Salary: $1,400,000.00
Bonus: $2,814,000.00
Joshua Smiley
Chief Financial Officer, Senior Vice President, Since 2018
Salary: --
Bonus: --
Jan Lundberg
Executive Vice President - Science and Technology, President - Lilly Research Laboratories, Since 2010
Salary: $1,024,640.00
Bonus: $1,373,020.00
Aarti Shah
Senior Vice President - Information Technology, and Chief Information Officer, Since 2018
Salary: --
Bonus: --
Melissa Barnes
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Lilly Corporate Ctr, Drop Code 1
INDIANAPOLIS   IN   46285

Phone: +1317.2762000

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

SPONSORED STORIES